SCHEMBL29327637

SCHEMBL29327637

Cc1cncc(-c2nc3cc(NC(=O)c4nc(C#N)ccc4S(C)(=O)=O)ccc3o2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.52
▸ MAPT P10636 12/20 0.47
▸ TP53 P04637 3/20 0.45
▸ POLB P06746 3/20 0.45
▸ HSD17B10 Q99714 6/20 0.44
▸ KDM4E B2RXH2 6/20 0.44
▸ NPSR1 Q6W5P4 3/20 0.44
▸ ALDH1A1 P00352 7/20 0.44
▸ NPC1 O15118 6/20 0.44
▸ RAB9A P51151 6/20 0.44
▸ SMN1; SMN2 Q16637 5/20 0.44
▸ SAE1 Q9UBE0 1/20 0.44
▸ UBA2 Q9UBT2 1/20 0.44
▸ THRB P10828 2/20 0.43
▸ HPGD P15428 5/20 0.43
▸ TSHR P16473 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327620 0.90 TP53 (0.54) PPARGMAPTTP53POLBHSD17B10
SCHEMBL29327616 0.89 TP53 (0.56) PPARGMAPTTP53POLBHSD17B10
SCHEMBL29327756 0.86 PPARG (0.55) PPARGMAPTTP53POLBHSD17B10
SCHEMBL29327627 0.85 MAPT (0.57) PPARGMAPTTP53POLBKDM4E
SCHEMBL29327596 0.85 PPARG (0.57) PPARGMAPTTP53POLBHSD17B10
SCHEMBL29327625 0.84 PPARG (0.60) PPARGMAPTTP53POLBNPC1
SCHEMBL29327624 0.83 MAPT (0.58) PPARGMAPTTP53HSD17B10KDM4E
SCHEMBL29327646 0.83 PPARG (0.53) PPARGMAPTTP53POLBKDM4E
SCHEMBL29327633 0.81 PPARG (0.54) PPARGMAPTTP53HSD17B10KDM4E
SCHEMBL29327628 0.81 MAPT (0.59) PPARGMAPTTP53HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885MAPT 4591/4885TP53 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback